Q2 2024 13F Holders as of 6/30/2024
-
Type / Class
-
Equity / Common Stock
-
Shares outstanding
-
48.5M
-
Number of holders
-
69
-
Total 13F shares, excl. options
-
32.2M
-
Shares change
-
-31.2K
-
Total reported value, excl. options
-
$78.7M
-
Value change
-
-$5.84M
-
Put/Call ratio
-
0.02
-
Number of buys
-
44
-
Number of sells
-
-24
-
Price
-
$2.44
Significant Holders of Werewolf Therapeutics, Inc. - Common Stock (HOWL) as of Q2 2024
85 filings reported holding HOWL - Werewolf Therapeutics, Inc. - Common Stock as of Q2 2024.
Werewolf Therapeutics, Inc. - Common Stock (HOWL) has 69 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 32.2M shares
of 48.5M outstanding shares and own 66.45% of the company stock.
Largest 10 shareholders include RA CAPITAL MANAGEMENT, L.P. (6.14M shares), MPM ASSET MANAGEMENT LLC (4.28M shares), PFM Health Sciences, LP (3.24M shares), MPM BIOIMPACT LLC (2.39M shares), BANK OF AMERICA CORP /DE/ (2.15M shares), ADAGE CAPITAL PARTNERS GP, L.L.C. (2M shares), BlackRock Inc. (1.59M shares), Rubric Capital Management LP (1.33M shares), VANGUARD GROUP INC (1.32M shares), and MILLENNIUM MANAGEMENT LLC (1.11M shares).
This table shows the top 69 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.